Avalo Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Avalo Therapeutics has a total shareholder equity of $22.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $98.5M and $75.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$81.86m |
| Equity | US$22.73m |
| Total liabilities | US$75.72m |
| Total assets | US$98.46m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: C6K0's short term assets ($86.1M) exceed its short term liabilities ($60.7M).
Long Term Liabilities: C6K0's short term assets ($86.1M) exceed its long term liabilities ($15.0M).
Debt to Equity History and Analysis
Debt Level: C6K0 is debt free.
Reducing Debt: C6K0 has no debt compared to 5 years ago when its debt to equity ratio was 84%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: C6K0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: C6K0 has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 12.2% each year.